Medimmune Limited

Boston Pharmaceuticals, Inc.

Abbott Laboratories Corporation

Reena Varkey

Partha S Chowdhury

Melissa Marie Damschroder

Bret Sellman

Xiaodong Xiao

Changshou Gao

Ralph Raymond Minter

Charles K Stover

Nazzareno Dimasi

Sandrine Guillard

Steven Rust

Antonio Digiandomenico

Mladen Tomich

Ryan Fleming

Paul Warrener

Binyam Bezabeh

Li Peng

Vignesh Venkatraman

Ronald Herbst

Godfrey Rainey

Stacey Drabic

Cuihua Gao

Qun Du

Ping Tsui

Catherine Ettinger

Jodi Karnell

Laura Carter

Brian Michael Naiman

Meina Liang

David Tice

Krista Lynne Kinneer

Koustubh Ranade

Yen-Wah Lee

Yihong Yao

Katie Streicher

Elaine M Hurt

Lydia Greenlees

Ethan Grant

Melissa Parker

Melissa Damschroder

Partha Chowdhury

Susan E Brophy

Christine Tkaczyk

Lei Hua

Vaheh Oganesyan

Bruce J Dille

Jamese Johnson Hilliard

Gerard Davis

Nicolette Jeanblanc

Rust Steven

Ralph Minter

Charles Stover

This disclosure relates to combination therapies comprising anti-Psl and PcrV binding molecules and related compositions, for use in prevention and treatment ofinfection.

Combination therapies using anti-pseudomonas PSL and PCRV binding molecules

The disclosure is directed to an antibody-drug conjugate (ADC) comprising a monoclonal antibody, or an antigen-binding fragment thereof, directed against B-cell maturation antigen (BCMA) conjugated to a cytotoxin. The disclosure also provides compositions comprising the antibody-drug conjugate and methods of killing multiple myeloma cells (including multiple myeloma stems cells) that express BCMA by contacting multiple myeloma cells with the ADC.

BCMA monoclonal antibody-drug conjugate

This disclosure provides IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof. In certain aspects the anti-IL-21 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects the binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof provided herein inhibit, suppress, or antagonize IL-21 activity. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders, e.g., inflammatory, immune-mediated, or autoimmune diseases or disorders associated with IL-21-mediated signal transduction. In a particular embodiment, the disclosure provides methods for treating or preventing Graft-versus-host disease (GVHD) using IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof.

Antibodies specific for IL-21 and uses thereof

This disclosure relates to polynucleotides encoding antibodies or antigen binding fragments thereof that bind toPcrV as well as vectors and host cells comprising the same.

Polynucleotides encoding antibodies or antigen binding fragments thereof that bind pseudomonas perv

This disclosure provides a robust, sensitive, and specific assay for the detection and measurement of periostin levels in samples obtained from human patients having, or suspected of having an IL-13-mediated disease or disorder. The disclosure further provides novel antiperiostin monoclonal antibodies that recognize at least isoforms 1, 2, 3, 4, 7, and 8 of human periostin, and assay kits comprising one or more of these antibodies.

Methods of using antibodies to determine periostin levels in a sample

Monoclonal antibodies which bind human periostin

The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making and using such proteins.

Multispecific and multivalent binding proteins and uses thereof

Herein provided are compositions, methods of manufacture and methods of use pertaining to anti-alpha toxin antibodies and fragments.

[object Object]

Growing community of inventors

Gaithersburg, MD, United States of America

Reena Varkey